New York, Feb 9, 2026, 19:11 EST — Trading in the after-hours session.
Shares of Johnson & Johnson (JNJ) slipped 0.6% to $238.64 in after-hours action Monday, as traders pulled back from healthcare stocks. The stock swung from $237.04 up to $240.74 over the session. Volume hit around 9.4 million shares.
The broader market stayed resilient, with SPDR S&P 500 ETF Trust (SPY) up 0.5%. The Invesco QQQ Trust (QQQ) did a bit better, adding 0.8%. Health care stocks struggled; the sector’s ETF, XLV, slipped 0.9%.
Johnson & Johnson is slated for a slot at the Barclays 28th Annual Global Healthcare Conference on March 10, where management will take questions in an 11:30 a.m. Eastern fireside chat. Investors can catch a live webcast through the company’s investor relations portal, and a replay should land roughly 48 hours after the event. 1
Merck tumbled 3.5%, dragging other major drugmakers lower. Pfizer edged down 0.7%, while Eli Lilly shed 1.3%.
J&J’s latest conference appearance follows January’s earnings report, which showed fourth-quarter sales reaching $24.6 billion and adjusted earnings at $2.46 a share. The company is targeting sales between $100.0 billion and $101.0 billion for 2026, with adjusted EPS guided to a range of $11.43 to $11.63. CEO Joaquin Duato described 2025 as “a catapult year.” 2
With thinner volumes after hours, even modest sentiment changes can move prices more than usual. Many traders, though, hold off until the market opens again to find out if those initial swings hold up.
Litigation still looms large. Johnson & Johnson faces over 67,500 lawsuits tied to its talc-based baby powder, maintaining the products are safe and cancer-free. Last week, a New Jersey appeals court kicked one plaintiffs’ firm off the state cases for an ethics violation—a move the firm plans to fight. 3
There’s another date to watch: Johnson & Johnson’s board has locked in a $1.30 per share quarterly dividend, due out March 10. The ex-dividend date lands on Feb. 24, stripping new buyers of the next payment, according to the company. 4
